Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous versus intravenous plerixafor for stem cell mobilization in HLA-identical sibling donors
NL-OMON20418Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of plerixafor in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), acute lymphoblastic leukemia (ALL) and 1 more (2 arms), sponsored by HOVON. Primary endpoint: Feasibility of stem cell mobilization and collection. Started Jul 2011; status: active, not recruiting.
02
Drugs
plerixafor
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NL-OMON20418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20418.